Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

NYP/Weill Cornell Medical Center, New York

Montefiore Medical Center-Einstein Campus, The Bronx

Montefiore Medical Center - Moses Campus, The Bronx

NYU Langone Hospital - Long Island, Mineola

MedStar Georgetown University Hospital, Washington D.C.

University of Kentucky/Markey Cancer Center, Lexington

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

Northwestern University, Chicago

Keck Medicine of USC Koreatown, Los Angeles

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

City of Hope Comprehensive Cancer Center, Duarte

City of Hope at Irvine Lennar, Irvine

USC Norris Oncology/Hematology-Newport Beach, Newport Beach

City of Hope Antelope Valley, Lancaster

Stanford Cancer Institute Palo Alto, Palo Alto

University of California Davis Comprehensive Cancer Center, Sacramento

University of Texas Medical Branch, Galveston